TETRAHYDROQUINAZOLINE DERIVATIVES AS CFR ANTAGONISTS
申请人:F.HOFFMANN-LA ROCHE AG
公开号:EP1656354A1
公开(公告)日:2006-05-17
US7223767B2
申请人:——
公开号:US7223767B2
公开(公告)日:2007-05-29
[EN] TETRAHYDROQUINAZOLINE DERIVATIVES AS CFR ANTAGONISTS<br/>[FR] DERIVES DE LA TETRAHYDROQUINAZOLINE EN TANT QU'ANTAGONISTES CFR
申请人:HOFFMANN LA ROCHE
公开号:WO2005014557A1
公开(公告)日:2005-02-17
Compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein m, R1, R2, R3 R4 and R6 are as defined herein. The invention also provides methods for preparing, compositions comprising the compounds of Formula (I), as well as their uses for the manufacture of medicaments useful in the treatment of diseases such as phobias, stress-related illnesses, mood disorders, eating disorders, generalized anxiety disorders, stress-induced gastrointestinal dysfunctions, neurodegenerative diseases, and neuropsychiatric disorders.
Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists
申请人:Clark Douglas Robin
公开号:US20050038052A1
公开(公告)日:2005-02-17
Compounds of the formula (I):
and pharmaceutically acceptable salts or prodrugs thereof, wherein m, R
1
, R
2
, R
3
, R
4
, R
5
and R
6
are as defined herein. The invention also provides methods for preparing, compositions comprising, and methods for using compounds of formula (I).
SmI2-mediated reductive cleavage of α-hetero substituents of α-alkyl or α-aryl ketones and lactone gave the corresponding “thermodynamic samarium enolates”. Enantioselective protonation of the samarium enolates with C2-symmetric chiral diols afforded the corresponding ketones and lactone in moderate to high enantioselectivities.